In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including: Contemporary treatment paradigms for patients with CLL Safety and efficacy of current regimens Molecular testing, including when and how to test for BTK inhibitor resistance Considering BTK inhibitor resistance when sequencing therapy Program faculty: Matthew S. Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Leader, Lymphoma Program Dana-Farber/Harvard Cancer Center Director of Clinical Research Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts Lindsey Roeker, MD Assistant Attending CLL Program Director Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Resources: To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page . Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
